F Lalloo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10991766/publications.pdf

Version: 2024-02-01

64 papers	7,358 citations	125106 35 h-index	124990 64 g-index
64 all docs	64 docs citations	64 times ranked	8002 citing authors

#	Article	IF	Citations
1	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	2.6	3,105
2	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	2.9	461
3	Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 2009, 75, 141-149.	1.0	280
4	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics, 2003, 40, 807-814.	1.5	261
5	Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer, 2012, 11, 235-242.	0.9	252
6	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of Medical Genetics, 2004, 41, 474-480.	1.5	232
7	Haplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study. American Journal of Human Genetics, 1998, 62, 1381-1388.	2.6	150
8	Familial Breast Cancer. Clinical Genetics, 2012, 82, 105-114.	1.0	147
9	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2318-2324.	1.1	132
10	Clinical follow-up after bilateral risk reducing (?prophylactic?) mastectomy: mental health and body image outcomes. Psycho-Oncology, 2000, 9, 462-472.	1.0	121
11	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	1.5	121
12	Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Journal of Medical Genetics, 2009, 46, 593-597.	1.5	116
13	Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. British Journal of Surgery, 2013, 100, 1719-1731.	0.1	104
14	Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics, 2006, 44, 10-15.	1.5	102
15	Risk of breast cancer in male BRCA2 carriers. Journal of Medical Genetics, 2010, 47, 710-711.	1.5	98
16	Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 2008, 74, 233-242.	1.0	85
17	Screening by mammography, women with a family history of breast cancer. European Journal of Cancer, 1998, 34, 937-940.	1.3	82
18	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2009, 46, 811-817.	1.5	80

#	Article	IF	Citations
19	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	1.5	80
20	Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2005, 42, e39-e39.	1.5	74
21	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. Journal of Medical Genetics, 2011, 48, 520-522.	1.5	69
22	TumourMLH1promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). Journal of Medical Genetics, 2014, 51, 789-796.	1.5	69
23	Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Disease, 2015, 17, 38-46.	0.7	63
24	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer, 2011, 105, 22-27.	2.9	60
25	Uptake of screening and prevention in women at very high risk of breast cancer. Lancet, The, 2001, 358, 889-890.	6.3	56
26	Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Disease Markers, 1999, 15, 207-211.	0.6	55
27	Risk assessment and management of high risk familial breast cancer. Journal of Medical Genetics, 2002, 39, 865-871.	1.5	53
28	Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. British Journal of Surgery, 2007, 94, 1009-1013.	0.1	53
29	The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut, 2010, 59, 1378-1382.	6.1	53
30	The spectrum of urological malignancy in Lynch syndrome. Familial Cancer, 2013, 12, 57-63.	0.9	50
31	Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer, 2001, 1, 65-72.	0.9	45
32	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Familial Cancer, 2015, 14, 531-538.	0.9	45
33	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. British Journal of Cancer, 2010, 102, 1091-1098.	2.9	42
34	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. European Journal of Surgical Oncology, 2005, 31, 1112-1118.	0.5	41
35	Genotypeâ€“phenotype correlation in colorectal polyposis. Clinical Genetics, 2012, 81, 521-531.	1.0	41
36	Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clinical Genetics, 2008, 73, 338-345.	1.0	38

#	Article	IF	Citations
37	Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer. Disease Markers, 1999, 15, 179-186.	0.6	35
38	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. European Journal of Surgical Oncology, 2000, 26, 711-713.	0.5	35
39	Breast cancer susceptibility variants alter risks in familial disease. Journal of Medical Genetics, 2010, 47, 126-131.	1.5	35
40	Utilisation of Prophylactic Mastectomy in 10 European Centres. Disease Markers, 1999, 15, 148-151.	0.6	29
41	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Research and Treatment, 2016, 155, 597-601.	1.1	29
42	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
43	Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 2012, 106, 775-779.	2.9	22
44	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Familial Cancer, 2014, 13, 189-196.	0.9	22
45	RASSF1A polymorphism in familial breast cancer. Familial Cancer, 2010, 9, 263-265.	0.9	19
46	Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey. Clinical Genetics, 2015, 87, 517-524.	1.0	18
47	Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. Journal of Medical Genetics, 2004, 41, 21e-21.	1.5	17
48	Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. Journal of Medical Genetics, 2000, 37, 792-794.	1.5	15
49	Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	1.1	15
50	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
51	Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families. Journal of Medical Genetics, 2003, 40, 107e-107.	1.5	13
52	Is multiple <scp>SNP</scp> testing in <scp>BRCA2</scp> and <scp>BRCA1</scp> female carriers ready for use in clinical practice? Results from a large Genetic Centre in the <scp>UK</scp>. Clinical Genetics, 2013, 84, 37-42.	1.0	12
53	TheBRCA2polymorphic stop codon: stuff or nonsense?. Journal of Medical Genetics, 2015, 52, 642-645.	1.5	12
54	An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.. Journal of Medical Genetics, 1998, 35, 10-12.	1.5	11

#	Article	IF	Citations
55	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 167, 779-785.	1.1	9
56	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 69-76.	0.5	9
57	Management of Hereditary Breast Cancer. Disease Markers, 1999, 15, 187-189.	0.6	8
58	BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. Journal of Medical Genetics, 2010, 47, 561-566.	1.5	7
59	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
60	Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. Genetics in Medicine, 2019, 21, 1878-1879.	1.1	6
61	Non-random transmission of mutant alleles to female offspring in BRCA carriers. Journal of Medical Genetics, 2005, 42, e6-e6.	1.5	5
62	Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs. Journal of the National Cancer Institute, 2002, 94, 307-307.	3.0	4
63	Breast cancer susceptibility variants alter risk in familial ovarian cancer. Familial Cancer, 2010, 9, 503-506.	0.9	4
64	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Familial Cancer, 2017, 16, 173-179.	0.9	2